NIH-funded research R21 grant

Creating synthetic versions of TDP-43 filaments linked to frontotemporal dementia

Official title: Synthetic replicas of TDP-43 filaments associated with frontotemporal dementia

Funded at Case Western Reserve University · NIH-11142330 · Data updated 2026-11-12

This study is looking at a protein called TDP-43 that builds up in the brains of people with frontotemporal dementia and other similar conditions, and the researchers want to create lab-made versions of this protein to better understand how it behaves, which could help in finding new treatments.

More Dementia research and trials

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionCase Western Reserve University
NIH-funded
Lab location1 site (Cleveland, United States)
Project startMay 15, 2025
Project endApril 30, 2027
Funding year2025
Award (this year)$442,750
NIH project number1R21AG094047-01
Project IDNIH-11142330 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with frontotemporal dementia, amyotrophic lateral sclerosis, or other neurodegenerative diseases associated with TDP-43 aggregation.

Less likely to help

Patients with neurodegenerative diseases not associated with TDP-43 aggregation may not benefit from this research.

What this research studies

This research focuses on understanding the accumulation of TDP-43 protein aggregates in the brain, which is a key feature of frontotemporal dementia and other neurodegenerative diseases. The researchers aim to develop synthetic replicas of these aggregates to study their structure and behavior. By using advanced techniques like cryo-electron microscopy, they will verify the similarity of these synthetic filaments to those found in patients' brains. This work could lead to new insights into the mechanisms of TDP-43 aggregation and pave the way for potential drug development.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that inhibit the harmful aggregation of TDP-43, potentially improving outcomes for patients with frontotemporal dementia and related conditions.

How similar studies have gone: Previous research has shown promise in understanding protein aggregation in neurodegenerative diseases, suggesting that this approach could yield valuable insights.

Where this research is happening

  • Case Western Reserve University
    Cleveland, United States
    Active

Researchers

  • Principal investigator: Surewicz, Witold K — Case Western Reserve University
  • Study coordinator: Surewicz, Witold K

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.